Your shopping cart is currently empty

Entospletinib (GS-9973) is a Syk inhibitor (IC50=7.7 nM) with selective, oral activity. Entospletinib has potential value in the treatment of a variety of hematological malignancies and immune-related diseases.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $32 | In Stock | In Stock | |
| 2 mg | $45 | In Stock | In Stock | |
| 5 mg | $74 | In Stock | In Stock | |
| 10 mg | $98 | In Stock | In Stock | |
| 25 mg | $178 | In Stock | In Stock | |
| 50 mg | $272 | In Stock | In Stock | |
| 100 mg | $438 | In Stock | In Stock | |
| 200 mg | $649 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $81 | In Stock | In Stock |
| Description | Entospletinib (GS-9973) is a Syk inhibitor (IC50=7.7 nM) with selective, oral activity. Entospletinib has potential value in the treatment of a variety of hematological malignancies and immune-related diseases. |
| Targets&IC50 | HUVECs:> 1000 nM (EC50), TF-1 cells:453 nM (EC50), MV-4-11 cells:327 nM (EC50), Ramos cells:2 nM (EC50), Bone marrow cells:582 nM, Syk:7.7 nM |
| In vitro | METHODS: NALM-6 and SEM cell lines were treated with Entospletinib (1, 5, and 10 μM) for 72 hours, and the expression levels of target proteins were detected using Western Blot. RESULTS: The expressions of key proteins including pAKT, pERK, pGSK3β, p53 and BCL-6 were significantly affected by Entospletinib. [1] |
| In vivo | METHODS: To investigate the anti-inflammatory activity of Entospletinib, Entospletinib (100 mg/kg) was administered orally twice daily to K/BxN serum-induced arthritis mice. RESULTS: Entospletinib significantly reduced macroscopic manifestations of joint inflammation, including joint swelling and clinical scores. [2] METHODS: To study the anti-inflammatory activity of Entospletinib, Entospletinib (10 mg/kg) was administered orally to a rat CIA model. RESULTS: Entospletinib showed significant anti-inflammatory effect. [3] |
| Kinase Assay | In the determination of full-length baculovirus expressed Syk kinase activity, the reaction system was 25 μL containing 25 mM Tris-HCl, pH 7.5, 5 mM β-glycerophosphate, 2 mM DTT, 0.1 mM Na3VO4, 10 mM MgCl2, 0.5 μM Promega PTK Biotin Peptide Substrate 1, 0.01% casein, 1, 0.01% Triton X-100, 0.25% Glycerol, and 40 mM ATP (Km for ATP). After incubation for 60 minutes at room temperature, the reaction was stopped by adding 30 mM EDTA (30 μL of SA-APC and 4 nM PT-66 antibody). After measuring the plate, the IC50 value of the test compound was calculated using a 4-parameter linear regression algorithm. |
| Cell Research | In MV-4-11 cells, the functional effect of the compound on the cellular Flt3 activity was determined by inhibition of cell proliferation. Cells were diluted in 96 well flat bottom tissue culture plates in RPMI medium containing 10% FBS and compound dilutions were added and incubated at 37°C for 72 hours. Aramazol (10%) was added to the cells and the cells were incubated for another 12-18 hours at 37°C. Finally, the inhibition of the relative cell number was measured at 570/600 nm in the spectrophotometer. |
| Animal Research | In the rat collagen-induced arthritis (CIA) model, Entospletinib (10 mg/kg), which is dissolved in hydrogenated castor oil,ethanol or physiological saline, is taken by oral. |
| Synonyms | GS-9973 |
| Molecular Weight | 411.46 |
| Formula | C23H21N7O |
| Cas No. | 1229208-44-9 |
| Smiles | C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1 |
| Relative Density. | 1.45 g/cm3 (Predicted) |
| Storage | keep away from direct sunlight,store at low temperature | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (121.52 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 2.5 mg/mL (6.08 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.